NASDAQ · Biotechnology

INMB (INMB) Stock

$1.73 +6.79% NASDAQ: INMB Healthcare

Valuation

MetricValue
Price$1.73
Market Cap$45.99M
P/E Ratio-2.44
P/B Ratio1.73
P/S Ratio776.29
EPS (TTM)$-0.53
52-Week High$11.64
52-Week Low$1.09
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-168.78%
ROA-52.61%
ROCE-134.78%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.08
Current Ratio3.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-29.0M$-26.0M$-30.0M$-43.0M$-31.0M
Net Profit$-30.0M$-27.0M$-30.0M$-42.0M$-46.0M
EPS$-1.88$-1.52$-1.67$-2.11$-1.86
Op Margin-16106.6%-6938.8%-19187.7%-304535.7%-61738.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$100.0M$82.0M$57.0M$40.0M$32.0M
Total Liabilities$20.0M$22.0M$19.0M$7.0M$9.0M
Cash$75.0M$52.0M$36.0M$21.0M$25.0M
Borrowings$15.0M$15.0M$10.0M$0$1.0M

Latest News

INmune Bio Says Study Shows Drug Candidate Reduced Alzheimer's-Related Brain Changes After Brain Injury MT Newswires · Jul 15, 2026 INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study GlobeNewswire · Jul 15, 2026 INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC GlobeNewswire · Jul 9, 2026 Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday MT Newswires · Jul 1, 2026 INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion GlobeNewswire · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-29.0M$-23.0M$-12.0M$-33.0M$-23.0M
Investing Cash Flow$-30.0M$0$0$0$-2.0M
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$53.0M$-23.0M$-16.0M$-15.0M$4.0M
Free Cash Flow$-44.0M$-23.0M$-12.0M$-33.0M$-24.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-61.06%
Quick Ratio4.24
Interest Coverage—
Return 1Y3.86%
Return 3Y-80.28%
Return 5Y-89.82%

Ownership

Insiders Held11.23%
Institutions Held19.68%
Institutions Float Held22.17%
Institutional HolderSharesReport Date
Blackrock Inc.1,194,1122026-03-31
Vanguard Capital Management LLC687,0152026-03-31
Geode Capital Management, LLC494,9692026-03-31
State Street Corporation290,8792026-03-31
AQR Capital Management, LLC270,3172026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGS $4.28 -1.04% -2.29 $26.45M 0.00%
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
CVM $1.18 +0.00% -0.23 $8.11M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
MRSNMersana Therapeutics, Inc. $29.08 +0.00% -2.59 $145.36M 0.00%

About INMB

INMB is led by CEO David J. Moss, publicly traded since 2019.

INMB stock trades at $1.73 with a market capitalization of $45.99M. The stock is valued at a price-to-earnings (P/E) ratio of -2.44, price-to-book of 1.73, price-to-sales of 776.29. Over the past 52 weeks the stock has ranged between $1.09 and $11.64, and currently trades 85.1% below its 52-week high.

On profitability, INMB generates a return on equity (ROE) of -168.78%, return on capital employed of -134.78%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides